Overview

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.
Treatments:
Clobetasol
Halobetasol